Oncology today looks vastly different than it did half a century ago, when patients had a 50% chance of surviving the next five years. In fact, between 1975 and 2016, the survival rate improved by 36% overall, thanks in large part to cutting-edge drug development. Such developments are dependent upon the success of clinical trials, including biomarker-driven precision oncology. So, how can biotech and pharma companies navigate the complex and ever-changing trial process to bring new treatments to market?
Join our host Dr. Stephen Gately, PhD, President & CEO of TD2, as he discusses the complex challenges of drug development and innovative technologies in a new podcast series dedicated to the evolution of oncology therapeutics.
Check out the podcast episodes below.⬆
- Ep. 1 Biomarkers and the utility of proteomics for dose optimization and confirmation of target engagement
- Ep. 2 The importance of metabolic and proteomic analyses in identifying treatment pathways for cancer patients
Biomarkers and the utility of proteomics for dose optimization and confirmation of target engagement
In this inaugural episode, Dr. Gately sits down with Dr. Emanuel “Chip” Petricoin, professor at George Mason University in the School of Systems Biology, Co-Director of the Center for Applied Proteomics and Molecular Medicine and founder and chairman of the scientific advisory board at Theralink Technologies. The two delve into a deep discussion on the development of Reverse Phase Protein Array technology, the importance of next generation sequencing in partnership with proteomic analyses, and much more.